finanzen.net
13.03.2018 21:30
Bewerten
(0)

Dr. Mathieu Simon to Retire as Cellectis’ Chief Operating Officer; Elsy Boglioli Named as Successor

DRUCKEN

Regulatory News:

Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced today that Dr. Mathieu Simon is retiring as Executive Vice President and Chief Operating Officer, effective immediately. Following a smooth and successful transition over the last few months, Elsy Boglioli, Executive Vice President, Strategy and Corporate Development, is named Chief Operating Officer.

"Dr. Simon has been incredibly instrumental in the strategic and operational direction of the therapeutic activities at Cellectis. Among his many achievements during his tenure, Dr. Simon helped to fundamentally transform Cellectis from a research-oriented biotech company to a clinical-stage biopharma player. I warmly thank him for his service,” said Dr. André Choulika, Cellectis Chief Executive Officer. "I look forward to Elsy Boglioli’s leadership as our new Chief Operating Officer as we enter the next phase of the Company’s development.”

Dr. Mathieu Simon has served as Cellectis’ Executive Vice President since 2012 and as Chief Operating Officer since 2013. He was a member of Cellectis’ board of directors as well.

"I am truly proud of our achievements at Cellectis over the last six years, including building a solid product candidate portfolio, advancing two allogeneic product candidates developed by Cellectis into the clinic and working strategically alongside our collaboration partners. It has been a great privilege to serve Cellectis and I am now ready to retire with enthusiasm for the Company’s future, confidence in the work that the Cellectis management team will continue, and gratitude for the many colleagues I have had the great pleasure to work with,” said Dr. Mathieu Simon. "I am delighted with Elsy Boglioli’s appointment as COO. Elsy brings a wealth of biopharmaceutical industry experience, having worked with leading pharmaceutical companies. Her unique blend of capabilities, relationships, and expertise will be invaluable assets to Cellectis.”

About Cellectis

Cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited T-cells (UCART). By capitalizing on its 18 years of expertise in gene editing – built on its flagship TALEN® technology and pioneering electroporation system PulseAgile – Cellectis uses the power of the immune system to target and eradicate cancer cells.

Using its life-science-focused, pioneering genome engineering technologies, Cellectis’ goal is to create innovative products in multiple fields and with various target markets.

Cellectis is listed on the Nasdaq market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more about us, visit our website: www.cellectis.com

Talking about gene editing? We do it. TALEN® is a registered trademark owned by Cellectis.

Disclaimer

This press release contains "forward-looking” statements that are based on our management’s current expectations and assumptions and on information currently available to management. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Further information on the risks factors that may affect company business and financial performance, is included in filings Cellectis makes with the Securities and Exchange Commission from time to time and its financial reports. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

Nachrichten zu CELLECTISAct. Nom.

  • Relevant
  • Alle
  • vom Unternehmen
  • Peer Group
  • ?

Keine Nachrichten im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten, die älter als ein Jahr sind, im Archiv

Um Ihnen die Übersicht über die große Anzahl an Nachrichten, die jeden Tag für ein Unternehmen erscheinen, etwas zu erleichtern, haben wir den Nachrichtenfeed in folgende Kategorien aufgeteilt:

Relevant: Nachrichten von ausgesuchten Quellen, die sich im Speziellen mit diesem Unternehmen befassen

Alle: Alle Nachrichten, die dieses Unternehmen betreffen. Z.B. auch Marktberichte die außerdem auch andere Unternehmen betreffen

vom Unternehmen: Nachrichten und Adhoc-Meldungen, die vom Unternehmen selbst veröffentlicht werden

Peer Group: Nachrichten von Unternehmen, die zur Peer Group gehören

Analysen zu CELLECTISAct. Nom.

  • Alle
  • Buy
  • Hold
  • Sell
  • ?
Keine Analysen gefunden.
mehr Analysen

Meistgelesene CELLECTISAct. Nom. News

Keine Nachrichten gefunden.
Weitere CELLECTISAct. Nom. News
Anzeige
Anzeige
Börse Stuttgart Anlegerclub

Fünf deutsche Internet-Aktien, die Sie kennen sollten!

Das Gute liegt oft so nah. Heimische Internet-Unternehmen rollen den Markt auf. Im neuen Anlegermagazin erwartet Sie ein Special über deutsche Internet-Aktien, die Sie kennen sollten.
Kostenfrei registrieren und lesen!

CELLECTISAct. Nom. Peer Group News

Keine Nachrichten gefunden.

Heute im Fokus

DAX geht mit Gewinnen ins Wochenende -- RWE: Vorzeitiges Aus für Hambach würde Milliarden kosten -- Uber könnte Deliveroo schlucken -- Tesla, Adobe, Amazon, Netflix im Fokus

HeidelbergCement verkauft Werk in Ägypten an Emaar Industries. Drei Novartis-Medikamente in Europa zur Zulassung empfohlen. Britisches Pfund nach May-Ansprache unter Druck. Bayer-Aktie: Mehr als nur Glyphosat-Risiken. Micron steigert Gewinn und Umsatz kräftig. DAX-Änderung ab Montag: Commerzbank steigt ab, Wirecard auf.

Umfrage

Die Parteien in Deutschland streiten sich um einen möglichen Militäreinsatz in Syrien. Was halten Sie davon?

Online Brokerage über finanzen.net

Das Beste aus zwei Welten: Handeln Sie für nur 5 Euro Orderprovision* pro Trade unmittelbar aus der Informationswelt von finanzen.net!
Zur klassischen Ansicht wechseln
Kontakt - Impressum - Werben - Pressemehr anzeigen
Top News
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Bitcoin
Goldpreis
Meistgesucht
Wirecard AG747206
Saint-Gobain S.A. (Compagnie de Saint-Gobain)872087
Deutsche Bank AG514000
Aurora Cannabis IncA12GS7
Daimler AG710000
Volkswagen (VW) AG Vz.766403
Amazon906866
Steinhoff International N.V.A14XB9
BYD Co. Ltd.A0M4W9
Apple Inc.865985
BayerBAY001
Deutsche Telekom AG555750
E.ON SEENAG99
CommerzbankCBK100
EVOTEC AG566480